Strategic Financial Concepts LLC purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 10,397 shares of the financial services provider’s stock, valued at approximately $1,375,000.
A number of other institutional investors have also made changes to their positions in the stock. Huntington National Bank lifted its stake in iShares Biotechnology ETF by 17.9% in the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after acquiring an additional 160 shares during the last quarter. National Bank of Canada FI raised its position in iShares Biotechnology ETF by 5.9% in the 3rd quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock valued at $600,000 after purchasing an additional 229 shares during the last quarter. Avior Wealth Management LLC raised its position in iShares Biotechnology ETF by 438.2% in the 3rd quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock valued at $470,000 after purchasing an additional 2,629 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund increased its stake in iShares Biotechnology ETF by 32.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after buying an additional 164,000 shares during the period. Finally, Main Management ETF Advisors LLC increased its stake in iShares Biotechnology ETF by 2.5% in the 3rd quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock valued at $86,395,000 after buying an additional 14,535 shares during the period. 62.45% of the stock is currently owned by institutional investors and hedge funds.
iShares Biotechnology ETF Stock Down 1.1 %
NASDAQ:IBB opened at $136.15 on Tuesday. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57. The firm’s fifty day simple moving average is $136.10 and its 200-day simple moving average is $141.27.
iShares Biotechnology ETF Cuts Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
Featured Stories
- Five stocks we like better than iShares Biotechnology ETF
- Trading Halts Explained
- Merck: 4 No-Brainer Reasons to Buy This Dip
- Ride Out The Recession With These Dividend Kings
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- What to Know About Investing in Penny Stocks
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.